More than 10 partner countries of the Russian Direct Investment Fund (RDIF) are studying Moscow’s experience for accelerated registration of vaccines against coronavirus. On August 28, RDIF CEO Kirill Dmitriev told reporters about it.
“Now more than 10 RDIF partner countries are studying the Russian experience for accelerated registration of drugs and vaccines against coronavirus with proven safety, based on proven solutions, such as human adenoviruses used in the Russian vaccine Sputnik V,” RIA Novosti reports.
The world’s first coronavirus vaccine was registered on August 11 in Russia. The drug was developed by specialists from the Gamaleya Center.
According to Russian President Vladimir Putin, the vaccine was registered in accordance with the laws of the country and world practice. He stressed that this was done on condition of further research of the drug in the course of mass use.
He also said that a vaccine developed by the Vector Institute in Novosibirsk will appear in September.
On July 27, the Novosibirsk Scientific Center of Virology and Biotechnology “Vector” began clinical trials of a vaccine against coronavirus. The corresponding permission was received on July 24. The second round of vaccine trials began on 17 August. According to the head of Rospotrebnadzor Anna Popova, all volunteers are doing well. Those who have received the vaccine do not have any reactions, there is not even a case of slight redness at the injection site.
Clinical trials of the vaccine are scheduled to be completed in September 2020.